Agape Pain Management and Anesthesia
- PRP Therapy
- Ketamine Therapy
- Arthritis Treatment
- Migraine Treatment
- Stem Cell Therapy
El Paso, NM
El Paso supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through Texas Tech University Health Sciences Center El Paso and The Hospitals of Providence, and stem cell practice in the area spans West Side, East Side, and the Medical Center of the Americas corridor. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. House Bill 810 (2017) permits licensed Texas physicians to administer investigational adult stem cell treatments for patients with severe chronic diseases or terminal illnesses under institutional review board oversight, without an FDA Investigational New Drug authorization. Texas Medical Board licensure is required, and advertising is regulated under the Texas Occupations Code. The 8 El Paso clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and Texas Medical Board licensure checks.
Regulatory context
New Mexico cellular therapy is governed by 21 CFR Part 1271. Section 361 covers minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 covers products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, and exosome therapies marketed in New Mexico for orthopedic, neurologic, and longevity indications are Section 351 biologics that lack FDA approval. New Mexico's regulatory environment relies on federal law and the Medical Practice Act.
The FDA has corresponded with New Mexico providers offering cellular therapies. The New Mexico Medical Board has authority to discipline physicians for unprofessional conduct including misleading regenerative medicine advertising. The New Mexico Attorney General can pursue deceptive marketing under the New Mexico Unfair Practices Act. New Mexico's smaller market means enforcement is less frequent than in larger states, but federal warning letters apply nationally.
Explore related care